



This is a repository copy of *The assessment of fetal brain growth in diabetic pregnancy using in utero magnetic resonance imaging.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/142284/>

Version: Accepted Version

Article:

Paddock, M., Akram, R., Jarvis, D.A. orcid.org/0000-0002-0133-1771 et al. (4 more authors) (2017) The assessment of fetal brain growth in diabetic pregnancy using in utero magnetic resonance imaging. *Clinical Radiology*, 72 (5). 427.e1-427.e8. ISSN 0009-9260

<https://doi.org/10.1016/j.crad.2016.12.004>

Article available under the terms of the CC-BY-NC-ND licence
(<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Clinical Radiology

The assessment of fetal brain growth in diabetic pregnancy using in utero magnetic resonance imaging --Manuscript Draft--

Manuscript Number:	
Full Title:	The assessment of fetal brain growth in diabetic pregnancy using in utero magnetic resonance imaging
Article Type:	Original Paper
Corresponding Author:	Michael Paddock University of Sheffield Sheffield, South Yorkshire UNITED KINGDOM
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Sheffield
Corresponding Author's Secondary Institution:	
First Author:	Michael Paddock
First Author Secondary Information:	
Order of Authors:	Michael Paddock Rahim Akram Deborah A Jarvis Paul Armitage Soon Song Priya Madhuvrata Paul D Griffiths
Order of Authors Secondary Information:	
Abstract:	<p>Aim: To assess fetal brain growth over the third trimester in pregnant women with diabetes using in utero magnetic resonance imaging (iuMR) to determine if greater brain growth occurs in type 1 (T1DM) when compared to gestational (GDM) diabetes.</p> <p>Materials and Methods: Each consented participant was scanned at three fixed times during the third trimester using iuMR. 157 patients were approached, 48 participants were recruited and 36 complete data sets were analysed. 3D iuMR volume data sets were manually segmented using software to construct models of the fetal brain from which brain volumes could be calculated. Inter-rater analysis was performed, and volume differences and growth rates were compared between T1DM and GDM.</p> <p>Results: Recruitment proved difficult with low uptake and high attrition rates (77.1%). Inter-rater analysis revealed excellent correlation (intraclass correlation coefficient=0.93, $p<0.001$) and agreement with no significant difference between operators ($p=0.194$). There was no evidence of increased brain volume in the T1DM group. Growth rates between visit 1 and 3 for T1DM and GDM were not significantly different ($p=0.095$).</p> <p>Conclusion: T1DM brain volumes were not significantly larger than GDM volumes and there was no significant divergence of brain growth over the third trimester. Constructing volume models from 3D iuMR acquisitions is a novel technique that can be used to assess fetal brain growth. No specialist software or knowledge is required. Larger studies attempting to recruit pregnant women in the later stages of pregnancy should employ multicentre recruitment to over-come recruitment difficulties and high attrition rates.</p>

The assessment of fetal brain growth in diabetic pregnancy using *in utero* magnetic resonance imaging

Michael Paddock ^{a,*}, Rahim Akram ^b, Deborah A Jarvis ^a, Paul Armitage ^a, Soon Song ^c, Priya Madhuvrata ^d, Paul D Griffiths ^a

^a Academic Unit of Radiology, University of Sheffield, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK

^b The Medical School, The University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK

^c Department of Diabetes and Endocrinology, Northern General Hospital, Sheffield, S5 7AU, UK

^d Department of Obstetrics & Gynaecology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, UK

***Guarantor and correspondent:** Dr Michael Paddock, Academic Unit of Radiology, University of Sheffield, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK
Telephone: +44 114 271 1643. Facsimile: +44 114 271 1714
E-mail: michael.paddock@doctors.org.uk

Funding information

This study was funded with the aid of a grant from the Royal College of Radiologists and the British Society of Neuroradiologists. The funders had no involvement in the study design, collection, analysis and interpretation of data, the writing of the report or in the decision to submit the article for publication. The study was sponsored by the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust.

Conflict of interest

The authors declare no conflict of interest.

Submission declaration

This article has not been published previously and is not under consideration elsewhere. Its publication is approved by all authors and explicitly by the responsible authorities where the work was carried out, and if accepted, will not be published elsewhere.

Acknowledgements

We would like to thank Dr Dinesh Selvarajah for his insights throughout the execution of this study. We are indebted to the specialist diabetes midwifery team at Sheffield Teaching Hospital NHS Foundation Trust, in particular Rebecca Bustani, Kimberley Clark and Frances Crawley, for their help with patient recruitment.

Author contributions

1. guarantor of integrity of the entire study – MP
2. study concepts and design – MP, SS, PA, PDG
3. literature research – MP, RA
4. clinical studies – PDG
5. experimental studies / data analysis – MP, PDG
6. statistical analysis – MP, RA, DJA, PDG
7. manuscript preparation – MP
8. manuscript editing – MP, RA, DJA, PA, SS, PM, PDG

ABSTRACT

Aim: To assess fetal brain growth over the third trimester in pregnant women with diabetes using *in utero* magnetic resonance imaging (*iuMR*) to determine if greater brain growth occurs in type 1 (T1DM) when compared to gestational (GDM) diabetes.

Materials and Methods: Each consented participant was scanned at three fixed times during the third trimester using *iuMR*. 157 patients were approached, 48 participants were recruited and 36 complete data sets were analysed. 3D *iuMR* volume data sets were manually segmented using software to construct models of the fetal brain from which brain volumes could be calculated. Inter-rater analysis was performed, and volume differences and growth rates were compared between T1DM and GDM.

Results: Recruitment proved difficult with low uptake and high attrition rates (77.1%). Inter-rater analysis revealed excellent correlation (intraclass correlation coefficient=0.93, $p<0.001$) and agreement with no significant difference between operators ($p=0.194$). There was no evidence of increased brain volume in the T1DM group. Growth rates between visit 1 and 3 for T1DM and GDM were not significantly different ($p=0.095$).

Conclusion: T1DM brain volumes were not significantly larger than GDM volumes and there was no significant divergence of brain growth over the third trimester. Constructing volume models from 3D *iuMR* acquisitions is a novel technique that can be used to assess fetal brain growth. No specialist software or knowledge is required. Larger studies attempting to recruit pregnant women in the later stages of pregnancy should employ multicentre recruitment to over-come recruitment difficulties and high attrition rates.

1 Introduction

2
3 Diabetes mellitus (DM) occurs in 2–5% of pregnant women in England and
4 Wales¹ of which approximately 87% have gestational diabetes (GDM), 8% type 1
5 diabetes (T1DM) and 5% type 2 diabetes (T2DM).² Pre-existing diabetes (T1DM and
6 T2DM) is associated with a number of risks to both mother and fetus including
7 miscarriage, pre-eclampsia, preterm labour, malformations and stillbirth.³⁻⁵ The risks
8 of perinatal complications in T1DM pregnancies are quoted as two to five times greater
9 than that of the general population,⁶ even in the presence of good glycaemic control
10 during pregnancy.⁷ Inadequate glycaemic control is associated with a higher risk of
11 recurrent miscarriage, stillbirth and congenital anomalies^{8,9} and is the most important
12 factor contributing to the increased risk of fetal and infant death in the absence of
13 congenital malformations.¹⁰

14 It is well established that women with DM tend to have larger fetuses and babies
15 (macrosomia) when compared to non-diabetic women.⁵ Whilst the overall size of a
16 fetus can be measured reliably ante-natally on ultrasonography, robust quantification
17 of brain volume is considerably more difficult, if not impossible, with that technique.
18 Surrogate measurements of fetal brain size in the literature are made by measuring
19 the biparietal diameter (BPD) on ultrasound. It has been shown that BPD
20 measurements are greater in those fetuses whose mothers have diabetes when
21 compared to normal pregnancies.^{11,12} The main problem is that there may be a
22 disconnect between skull growth and brain growth; the BPD, as a subjective/operator
23 dependant ultrasound assessment, is a poor indicator of 'brain size'. By comparison,
24 *in utero* magnetic resonance (*iuMR*) imaging provides a comprehensive cross-
25 sectional evaluation which has been shown to be superior in the assessment of the

26 fetal brain and the detection of abnormalities.¹³⁻¹⁶ Recent advances in *iuMR* imaging,
27 in particular, rapid T2 weighted three-dimensional (3D) volume sequences, have
28 allowed detailed assessment of the fetal brain,¹⁷ facilitating estimation of brain volume
29 (distinct from skull measurements) and the ability to assess brain maturity in terms of
30 gyration/sulcation.

31 No data currently exists regarding brain volumes and the rate of fetal brain
32 growth during third trimester pregnancy in DM. In this study, we assessed third
33 trimester fetal brain growth (volume, as measured by *iuMR*) in women with DM to
34 assess when, and if, differential brain growth occurs.

35

36 **Materials and Methods**

37

38 *Participants and recruitment*

39

40 The study population comprised of women with diabetes (T1DM, T2DM and
41 GDM) who attended specialist antenatal clinics and workshops at our institution.
42 Inclusion criteria were: maternal age >16 years at time of recruitment; normal anomaly
43 ultrasound scan at 20 gestational weeks (GW); singleton pregnancy; between 20 and
44 28 GW at the time of recruitment. Exclusion criteria were: inability to speak fluent
45 English (therefore unable to provide independent informed consent); contraindications
46 to *iuMR* imaging. Potential participants were given an information leaflet on *iuMR*
47 scanning, were contacted after 48 hours and offered three sequential MR
48 examinations at GW 28±1 (visit 1), 31±1 (visit 2) and 34±1 (visit 3). Complete data
49 sets were excluded if they fell outside these predefined timings. Recruitment occurred
50 over a 20-month period from 2013 to 2015. Local institutional ethical approval was

51 obtained but did not allow for consecutive scanning of 'normal'/non-diabetic pregnant
52 women. As such, pregnant women with GDM acted as a 'disease control' given that
53 they are much less likely to have large babies compared to women with pre-existing
54 diabetes.¹⁸⁻²¹ Informed consent was obtained during the first pre-scan discussion in
55 addition to formal MR safety screening which was performed at least twice prior to
56 scanning.

57

58 *MR imaging*

59

60 All *iuMR* imaging was performed on the same whole body 1.5T GE HDx
61 (General Electric Healthcare, Milwaukee, WI) scanner using an eight-channel cardiac
62 phased-array coil. No maternal sedation was used. Following routine imaging of the
63 fetal brain, 3D volumetric data sets were acquired using the Fast Imaging Employing
64 Steady-state Acquisition (FIESTA) sequence in the axial plane relative to the fetal
65 brain.¹⁷ Imaging parameters were: 4-5 ms minimum repetition time (TR); 2-3 ms
66 minimum echo time (TE); refocusing flip angle of 60°; 0.75 number of excitations
67 (NEX); field of view (FOV) 340 x 270 mm; matrix size of 320 x 256 mm. Partition
68 thickness was 1.8-2.2 mm with 28-32 scan locations per slab dependent on fetal brain
69 size. In order to allow full coverage of the fetal brain with maximal resolution, the
70 section thickness or number of scan locations was adjusted and achieved in a
71 timeframe conducive to a maternal breath-hold (20-23 s).

72 A report was issued for all scans by a neuroradiologist (PDG, over 15 years of
73 fetal neuroradiology experience) stating that the procedure was performed for
74 research purposes. If no brain abnormality was shown, 'no unexpected abnormalities'
75 was reported. If there was a further intracranial abnormality, a full clinical report was

76 provided directly to the patient's obstetrician. Each participant was invited back for
77 further scan(s) according to the predefined time limits above, however they were under
78 no obligation to do so. A complete data set comprised of three consecutive *iuMR*
79 scans.

80

81 *Post-processing and statistical analysis*

82

83 All imaging was anonymised, reformatted, transferred onto a desktop personal
84 computer and loaded into three-dimensional (3D) reconstruction software
85 (www.slicer.org). As shown in Fig. 1a-1d, the ventricles, cerebral hemispheres,
86 cerebellum and extracranial cerebrospinal fluid volume were delineated by hand on
87 every axial slice in the volumetric MR acquisition by trained operators involved in the
88 study (DAJ, experienced operator {operator 1}; RA, newly trained {operator 2}). The
89 volumetric data for qualitative analysis were generated from surface rendered 3D
90 models for each area of delineated anatomical interest, as shown in Fig. 1e and 1f.
91 This method is based on previously published work from our institution.²²

92 Fourteen data sets from visit 1 were measured separately by the two operators
93 for inter-rater analysis (all seven T1DM and seven randomly selected GDM cases).
94 Independent *t*-tests were used to compare percentage differences and intraclass
95 correlation coefficient (ICC) was calculated to assess correlation. A Bland-Altman plot
96 was constructed to assess agreement, variability and bias.

97 Total parenchymal brain volume (TPBV) was derived from the difference
98 between the total brain volume (both cerebral hemispheres and cerebellum) and the
99 internal (ventricular) cerebrospinal fluid volume: the TPBV 3D model is shown in Fig.
100 1f. Independent *t*-tests were employed to evaluate any differences in fetal brain growth

101 between both groups. The difference between individual fetal brain volumes were
102 calculated between visits 1 and 3 and divided by the number of weeks (6 weeks) to
103 calculate rates of brain growth. $p < 0.05$ was considered statistically significant and the
104 p values were 1-sided to provide more power to detect an effect. Statistical analysis
105 was performed using SPSS 22 (SPSS, Chicago, IL).

106

107 **Results**

108

109 Over the 20-month recruitment period, 157 pregnant women with DM were
110 approached for potential recruitment (106 with GDM, 22 with T1DM and 29 with
111 T2DM). Of those, 48 gave consent for participation (age range 21 to 45 years). 12
112 incomplete data sets were excluded leaving 36 complete data sets available for
113 analysis: $n=29$, GDM (age range 21 to 44 years); $n=7$, T1DM (age range 23 to 37
114 years); $n=0$, T2DM. The recruitment and attrition rates are outlined in Fig. 2.

115 One fetus from a pregnant woman with T1DM had unilateral mild
116 ventriculomegaly (defined by trigone measurements ≥ 10 mm) diagnosed on visit 1
117 *iuMR* imaging: the trigone of the left lateral ventricle measured 11mm and the right
118 trigone measured 6mm. The ventriculomegaly persisted throughout the study period
119 measuring 11mm on visit 2 and 10mm on visit 3 *iuMR* imaging. No other structural
120 brain abnormalities were shown.

121 Inter-rater analysis is shown in Table 1. No statistically significant difference
122 was found: $t(26)=0.88$, $p=0.194$ (95% confidence interval (CI), -5.52 to 13.78). The
123 average measure ICC was 0.93, $p < 0.001$ (95% CI, 0.643 to 0.981). The corresponding
124 Bland-Altman plot (Fig. 3) illustrates that all values lie within the 95% confidence limits

125 with a degree of bias towards the results of the more experienced operator 1 (10 data
126 points lie above zero).

127 Fig. 4 illustrates the distribution of TPBV at each visit. The visit 1 GDM TPBV
128 was statistically significantly higher than T1DM ($p=0.020$). The possible relevance of
129 this apparently spurious result is described below. There was no statistically significant
130 difference between GDM and T1DM brain volumes at visit 2 ($p=0.456$) and visit 3
131 ($p=0.053$). The growth rates ($\text{cm}^3/\text{week} \pm$ standard deviation) between visit 1 and 3
132 were not statistically significantly different (GDM, 17.39 ± 0.64 ; T1DM, 18.24 ± 3.15 ;
133 $t(33.8)=1.34$, $p=0.095$).

134

135 Discussion

136

137 This study highlights the difficulty in recruiting pregnant women with DM into
138 *iuMR* studies, relevant when attempting to perform a study from a single centre. We
139 found that it was easier to recruit women from workshops that were less time-
140 pressured when compared with busy clinics. Over the 20-month recruitment period,
141 157 potential participants were approached. After formal discussion and allowing
142 sufficient time for consideration, the rate of consented participants was low ($n=48/157$,
143 30.6%). Once consented, the retention rate was relatively high ($n=36/48$, 75%);
144 reasons for incomplete data sets are provided in Fig. 2. The overall attrition rate from
145 approach to completion was far lower than expected ($n=36/157$, 77.1%) and only 36
146 complete data sets were acquired, i.e. less than 2 per month.

147 Participants were not asked about their reasons for withdrawing/not
148 attending/not wanting to book further scans but some offered reasons without
149 prompting: childcare issues; previous miscarriage, worried about the long term effects

150 of MR; claustrophobic, could not tolerate further scans; time commitments as still
151 working; too many other appointments. Some commented that a significant attraction
152 of this study was direct funding/reimbursement of all travel expenses. Given that
153 recruitment and retention from this patient group is difficult, the research design of any
154 larger study would need to be dynamic and flexible. Furthermore, formal qualitative
155 assessment should be undertaken through formal patient and public information (PPI)
156 engagement with specific reference to the acceptability of consecutive *iuMR* scanning
157 in third trimester pregnancies to address the practicality and viability of a larger scale
158 study.

159 The high proportion of pregnant women with GDM who were approached,
160 consented and retained for final analysis is similar to the reported prevalence in the
161 general population.¹ The difficulties of recruiting pregnant women into research
162 studies is well documented,²³⁻²⁶ particularly during the third trimester with high attrition
163 rates also reported.²⁷ This was the first study from our unit attempting to recruit
164 pregnant women for consecutive third trimester *iuMR* scanning, which to our
165 knowledge no reported study has previously attempted. It is clear that future studies
166 attempting to recruit women for consecutive *iuMR* third trimester scanning would need
167 to employ multicentre recruitment to allow for potentially suboptimal participation and
168 high attrition, in addition to funding travel expenses. The links forged from previous
169 multicentre work co-ordinated at our institution would facilitate this process.²⁸

170 Inter-rater analysis allows us to assess the reliability (inherent repeatability) and
171 precision of the 3D volumetric measurements between operators so that our results
172 have external validity (generalisability). All inter-rater percentage differences between
173 both operators varied by less than $\pm 10\%$, with half varying by less than $\pm 5\%$ and there
174 was excellent correlation (ICC 0.93, $p < 0.001$). The Bland-Altman plot (Fig. 3)

175 demonstrated that the mean differences became slightly larger as the mean volume
176 increased. However, given the small sample size ($n=14$) and with all results within the
177 narrow limits of agreement, any bias or variability demonstrated by Operator 1 is very
178 unlikely to be clinically or practically significant which is important when considering
179 the generalisability of this technique. Furthermore, we demonstrated no statistically
180 significant difference between the volume data measurements between both
181 operators ($p=0.194$).

182 Factors contributing to variability or bias centred around the segmentation
183 process and accurate delineation of structures at 'true' interfaces, i.e. parenchymal-
184 cerebrospinal fluid interface, noted to be most difficult at the trigonal ventricular choroid
185 plexus-periventricular white matter interface. Other factors included: fetal and/or
186 maternal movement artefact resulting in poor image quality; subjective differences in
187 contrast and brightness settings which can be altered at any time during segmentation;
188 changes in ambient lighting; visual and muscular fatigue when segmenting older
189 gestational fetal brains because of the more complex sulcation pattern.

190 Previous studies have demonstrated that neonates born to diabetic mothers
191 have larger head circumferences when compared to those born to non-diabetic
192 mothers,²⁹ interpreted to indicate that they would have larger brains. Our assumption
193 before this study commenced was that T1DM fetuses would have larger brain volumes
194 when compared to GDM/normal brains, although we did not know at what gestational
195 age this difference would become apparent. In spite of the lack of supporting data from
196 antenatal ultrasound, we predicted that any statistically significant differences in brain
197 volume would be apparent by visit 3 (34 ± 1 GW) given that maximal neural growth and
198 development occurs during this period.³⁰ Brain volumes in fetuses of women with
199 T1DM however were not significantly larger than those with GDM and there was no

200 significant difference in the rate of growth between 28 to 34 GW. It is likely therefore
201 that the divergence in brain growth could be found beyond 35 weeks given the larger
202 head size in T1DM neonates at birth.^{11,29} Contrary to our expectation, the T1DM mean
203 TPBV at visit 1 (28±1 GW) was statistically significantly smaller than that of GDM
204 (p=0.020). There is no supporting evidence in the literature that BPD measurements
205 on ultrasound are smaller in fetuses of mothers with T1DM than their GDM
206 counterparts, and given the small sample size (n=7 in the T1DM group), this is
207 probably a spurious result. This time point (28±1 GW) could be further re-examined in
208 a larger study to determine the time point at which differential brain growth occurs.
209 Recent literature has debated the impact of endothelial dysfunction on umbilical
210 arteries in pre-existing DM.^{31,32} Blood flow is more critical for organ development
211 earlier in pregnancy and the subsequent dysregulation in umbilical blood flow may
212 result in underdevelopment of the fetal brain. It is possible that this is more pronounced
213 in brains of fetuses whose mothers have T1DM, such that from a metabolic
214 perspective there is more physiological ‘catching up’ to do *in utero* which is
215 compensated for in later pregnancy (≥36 GW). This may explain why those born to
216 mothers with DM have bigger heads and are larger than their non-diabetic
217 counterparts. Evidently, the underlying physiological mechanism warrants further
218 investigation in addition to an assessment of fetal brain growth not captured in this
219 study.

220 As previously discussed, initial recruitment proved difficult and many data sets
221 remained incomplete due to patient withdrawal. In order to recruit sufficient numbers,
222 the list of possible participants was discussed with the specialist diabetes midwifery
223 team at the start of each specialist clinic or workshop. Given the time and expense
224 involved in performing 3 *iuMR* scans, we sought to recruit patients invested in

225 completing all 3 scans in order to obtain complete data sets. As such, those known to
226 the local service with a history of non-compliance, who frequently missed
227 appointments and with complex social issues were deemed not appropriate to
228 approach. However, even in spite of this, some of the latter recruited participants still
229 did not attend all three scans or withdrew.

230 The sample size (n=36) was not large enough to capture any results that were
231 likely to be that clinically meaningful however this data can be used to power a larger
232 study. As described above, an assessment of late third trimester diabetic pregnancies
233 (>35 GW) may elucidate the point at which differential brain growth occurs. A larger
234 study should encompass the influence of maternal factors on brain growth and
235 maturation including: weight (body mass index); type and/or combination of
236 management of diabetes in pregnancy (diet controlled, oral hypoglycaemics, insulin);
237 quality of glycaemic control, particularly considering that even in the presence of an
238 overall good level of glycaemic control the frequency of macrosomia remains high.^{33,34}

239 Alongside the 3D *iu*MR data sets, the 3D surface rendering of the fetal brain²²
240 could be used to estimate the gestational age of the fetus based on its sulcation
241 pattern, comparing to standard atlases and actual gestational age. An assessment of
242 brain maturation rate between the different types of diabetes could also be performed
243 which would allow further development of a fetal brain maturation database and
244 subsequent validation of a fetal brain maturation scoring system building upon
245 previously published work in this area.³⁵

246 The novel techniques described could be expanded to assess the effect of
247 conditions known to affect fetal growth during pregnancy: placental insufficiency; intra-
248 uterine growth restriction in both singleton and multiple pregnancies; baseline growth
249 differences in twin pregnancy; twin-to-twin transfusion syndrome.

250

251 **Conclusion**

252

253 We have shown that 3D volumetric modelling from manually segmented 3D
254 *iuMR* acquisition is a reliable and reproducible technique. Users with no prior
255 knowledge of the software or technique can be trained to use the programme to
256 produce reliable results. The method does not require specialist computer software
257 (3D slicer is freely available) or specialist knowledge to operate. This technique can
258 be implemented in the clinical environment with wide-range applicability for use by any
259 healthcare professional. With regard to fetal brain growth and maturation, it is clear
260 that more work in this area is needed and that larger studies would need to employ
261 multicentre recruitment and encompass a flexible research design.

262

263

264 **References**

265

- 266 1. NICE. Diabetes in pregnancy: management from preconception to the
267 postnatal period (NG3). <https://www.nice.org.uk/guidance/ng3> (Accessed: 5
268 July 2016). Published: February 2015. Last updated: August 2015.
- 269 2. Magon N, Chauhan M. Pregnancy in Type 1 Diabetes Mellitus: How Special
270 are Special Issues? *N Am J Med Sci*. 2012; 4(6):250-256.
- 271 3. Hawthorne G, Robson S, Ryall EA, Sen D, Roberts SH, Ward Platt MP.
272 Prospective population based survey of outcome of pregnancy in diabetic
273 women: results of the Northern Diabetic Pregnancy Audit, 1994. *British*
274 *Medical Journal*. 1997; 315(7103):279-281.
- 275 4. Negrato CA, Mattar R, Gomes MB. Adverse pregnancy outcomes in women
276 with diabetes. *Diabetol Metab Syndr*. 2012; 4(1):41.
- 277 5. Nold JL, Georgieff MK. Infants of diabetic mothers. *Pediatric clinics of North*
278 *America*. 2004; 51(3):619-637, viii.
- 279 6. Colstrup M, Mathiesen ER, Damm P, Jensen DM, Ringholm L. Pregnancy in
280 women with type 1 diabetes: have the goals of St. Vincent declaration been
281 met concerning foetal and neonatal complications? *The journal of maternal-*
282 *fetal & neonatal medicine : the official journal of the European Association of*
283 *Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies,*
284 *the International Society of Perinatal Obstet*. 2013; 26(17):1682-1686.

- 285 7. Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in
286 women with type 1 diabetes: nationwide prospective study in the Netherlands.
287 *Bmj*. 2004; 328(7445):915.
- 288 8. Azar M, Lyons TJ. Management of pregnancy in women with type 1 diabetes.
289 *Minerva endocrinologica*. 2013; 38(4):339-349.
- 290 9. Allen VM, Armson BA, Wilson RD, et al. Teratogenicity associated with pre-
291 existing and gestational diabetes. *Journal of obstetrics and gynaecology*
292 *Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC*.
293 2007; 29(11):927-944.
- 294 10. Tennant PW, Glinianaia SV, Bilous RW, Rankin J, Bell R. Pre-existing
295 diabetes, maternal glycated haemoglobin, and the risks of fetal and infant
296 death: a population-based study. *Diabetologia*. 2014; 57(2):285-294.
- 297 11. Wong SF, Lee-Tannock A, Amaraddio D, Chan FY, McIntyre HD. Fetal growth
298 patterns in fetuses of women with pregestational diabetes mellitus. *Ultrasound*
299 *Obstet Gynecol*. 2006; 28(7):934-938.
- 300 12. Murata Y, Martin CB, Jr. Growth of the biparietal diameter of the fetal head in
301 diabetic pregnancy. *Am J Obstet Gynecol*. 1973; 115(2):252-256.
- 302 13. Morris JE, Rickard S, Paley MN, Griffiths PD, Rigby A, Whitby EH. The value
303 of in-utero magnetic resonance imaging in ultrasound diagnosed foetal
304 isolated cerebral ventriculomegaly. *Clinical radiology*. 2007; 62(2):140-144.
- 305 14. Rich P, Jones R, Britton J, Foote S, Thilaganathan B. MRI of the foetal brain.
306 *Clinical radiology*. 2007; 62(4):303-313.
- 307 15. Williams F, Griffiths PD. The diagnosis of hemimegalencephaly using in utero
308 MRI. *Clinical radiology*. 2014; 69(6):e291-297.
- 309 16. Craven I, Bradburn MJ, Griffiths PD. Antenatal diagnosis of agenesis of the
310 corpus callosum. *Clinical radiology*. 2015; 70(3):248-253.
- 311 17. Griffiths PD, Jarvis D, McQuillan H, Williams F, Paley M, Armitage P. MRI of
312 the foetal brain using a rapid 3D steady-state sequence. *The British journal of*
313 *radiology*. 2013; 86(1030):20130168.
- 314 18. Ehrenberg HM, Mercer BM, Catalano PM. The influence of obesity and
315 diabetes on the prevalence of macrosomia. *Am J Obstet Gynecol*. 2004;
316 191(3):964-968.
- 317 19. Lawlor DA, Fraser A, Lindsay RS, et al. Association of existing diabetes,
318 gestational diabetes and glycosuria in pregnancy with macrosomia and
319 offspring body mass index, waist and fat mass in later childhood: findings from
320 a prospective pregnancy cohort. *Diabetologia*. 2010; 53(1):89-97.
- 321 20. Jolly MC, Sebire NJ, Harris JP, Regan L, Robinson S. Risk factors for
322 macrosomia and its clinical consequences: a study of 350,311 pregnancies.
323 *Eur J Obstet Gynecol Reprod Biol*. 2003; 111(1):9-14.
- 324 21. Ehrenberg HM, Durnwald CP, Catalano P, Mercer BM. The influence of
325 obesity and diabetes on the risk of cesarean delivery. *Am J Obstet Gynecol*.
326 2004; 191(3):969-974.
- 327 22. Jarvis DA, Armitage P, Dean A, Griffiths PD. Surface reconstructions of foetal
328 brain abnormalities using ultrafast steady state 3D acquisitions. *Clinical*
329 *radiology*. 2014; 69(10):1084-1091.
- 330 23. Sadeghi A, Sirati-Nir M, Ebadi A, Aliasgari M, Hajiamini Z. The effect of
331 progressive muscle relaxation on pregnant women's general health. *Iran J*
332 *Nurs Midwifery Res*. 2015; 20(6):655-660.

- 333 24. Ekstrom EC, Hyder SM, Chowdhury AM, et al. Efficacy and trial effectiveness
334 of weekly and daily iron supplementation among pregnant women in rural
335 Bangladesh: disentangling the issues. *Am J Clin Nutr.* 2002; 76(6):1392-1400.
- 336 25. Mukhopadhyay A, Bhatla N, Kriplani A, Agarwal N, Saxena R. Erythrocyte
337 indices in pregnancy: effect of intermittent iron supplementation. *Natl Med J*
338 *India.* 2004; 17(3):135-137.
- 339 26. Ridwan E, Schultink W, Dillon D, Gross R. Effects of weekly iron
340 supplementation on pregnant Indonesian women are similar to those of daily
341 supplementation. *Am J Clin Nutr* 1996; 884-890. Available at:
342 <http://www.ncbi.nlm.nih.gov/pubmed/8644682>. Accessed 6, 63.
- 343 27. Foulon S, Greacen T, Pasquet B, et al. Predictors of Study Attrition in a
344 Randomized Controlled Trial Evaluating a Perinatal Home-Visiting Program
345 with Mothers with Psychosocial Vulnerabilities. *PLoS One.* 2015;
346 10(11):e0142495.
- 347 28. Griffiths PD. On behalf of the MERIDIAN Study Group. Protocol 11PRT/2491:
348 Magnetic Resonance Imaging to Enhance the Diagnosis of Fetal
349 Developmental Brain Abnormalities in Utero (MERIDIAN)
350 (ISRCTN27626961). <http://www.thelancet.com/protocol-reviews/11PRT-2491>
351 (Accessed: 5 July 2016). Published: March 2011.
- 352 29. Persson M, Pasupathy D, Hanson U, Norman M. Birth size distribution in
353 3,705 infants born to mothers with type 1 diabetes: a population-based study.
354 *Diabetes Care.* 2011; 34(5):1145-1149.
- 355 30. Linderkamp O, Janus L, Linder R, Skoruppa DB. Time Table of Normal Foetal
356 Brain Development. *Int. J. Prenatal and Perinatal Psychology and Medicine.*
357 2009; 21(1/2):4-16.
- 358 31. Li J, Chen YP, Dong YP, et al. The impact of umbilical blood flow regulation
359 on fetal development differs in diabetic and non-diabetic pregnancy. *Kidney*
360 *Blood Press Res.* 2014; 39(4):369-377.
- 361 32. Vambergue A, Fajardy I. Consequences of gestational and pregestational
362 diabetes on placental function and birth weight. *World J Diabetes.* 2011;
363 2(11):196-203.
- 364 33. Lepercq J, Taupin P, Dubois-Laforgue D, et al. Heterogeneity of fetal growth
365 in type 1 diabetic pregnancy. *Diabetes Metab.* 2001; 27(3):339-344.
- 366 34. Wong SF, Chan FY, Oats JJ, McIntyre DH. Fetal growth spurt and
367 pregestational diabetic pregnancy. *Diabetes Care.* 2002; 25(10):1681-1684.
- 368 35. Vossough A, Limperopoulos C, Putt ME, et al. Development and validation of
369 a semiquantitative brain maturation score on fetal MR images: initial results.
370 *Radiology.* 2013; 268(1):200-207.

371

372

373

374

375

376

377

378 **Figures Legends**

379

380 **Figure 1.** An example of the manual segmentation and construction of brain models
381 from which the total parenchymal brain volume (TPBV) was calculated. Figures 1a –
382 1d are the same axial slice from a 3D FIESTA acquisition of a 29 week fetus from a
383 woman with gestational diabetes. (a) Delineation of the internal cerebrospinal fluid
384 (ventricular) volume (blue), (b) right hemisphere (gold), (c) left hemisphere (cream)
385 and (d) external cerebrospinal fluid (extracranial) volume (red). The cerebellum is also
386 segmented (green, not shown in these images). Segmentation is performed on all
387 slices in the volume acquisition and models of the ventricles (e) and whole brain (f)
388 are created. The models generate quantitative volumetric data for each area. The
389 TPBV is derived from the difference between the total brain volume (both cerebral
390 hemispheres and cerebellum) and the internal (ventricular) cerebrospinal fluid volume.

391

392

393 **Figure 2.** Flowchart outlining recruitment and attrition. GDM=gestational diabetes
394 mellitus. T1DM=type 1 diabetes mellitus. T2DM=type 2 diabetes mellitus.

395

396

397 **Figure 3.** Bland-Altman plot of differences between operator 1 (DAJ, experienced)
398 and 2 (RA, newly trained). Solid black line=mean. Dashed lines=95% limits of
399 agreement.

400

401

402

403 **Figure 4.** Box-and-whisker plot illustrating the total brain parenchymal volume (TPBV)
404 over the course of the third trimester at each visit by type of diabetes mellitus. Visit 1
405 (gestational weeks)=28±1. Visit 2=31±1. Visit 3=34±1. The visit 1 GDM TPBV was
406 significantly higher than T1DM ($t(34)=2.15$, $p=0.020$, 95% confidence interval (CI) -
407 22.52 to -0.62). There was no significant difference between GDM and T1DM brain
408 volumes at visit 2 ($t(34)=0.11$, $p=0.456$, 95% CI -17.96 to 16.09) and visit 3 ($t(34)=1.17$,
409 $p=0.053$, 95% CI -17.34 to 1.71).


410


411


412 **Table Legend**


413

414 **Table 1.** Percentage differences for 14 selected volumes (seven T1DM and seven
415 randomly selected GDM cases) from visit 1 (28±1 gestational weeks) between two
416 operators involved in the study. Operator 1=DAJ. Operator 2=RA.









Participant number	Operator 1 volumes (cm ³)	Operator 2 volumes (cm ³)	% difference (cm ³)
1	134.55	139.70	3.83
11	127.17	126.07	-0.86
14	130.44	129.42	-0.78
17	123.19	132.45	7.52
22	137.08	144.37	5.32
24	151.97	164.12	7.99
25	133.93	141.36	5.55
32	121.81	128.66	5.62
35	142.51	151.42	6.25
36	126.49	123.78	-2.14
37	126.23	133.10	5.44
39	155.66	156.53	0.56
44	154.28	156.99	1.76
45	150.72	145.90	-3.20
Mean	136.86	140.99	3.06

HIGHLIGHTS

- No differential brain growth occurs over the third trimester of diabetic pregnancy
- Manual segmentation of 3D *iuMR* acquisitions requires no specialist knowledge
- 3D volume modelling of the fetal brain is a reliable and reproducible technique